Author

A. Schlegel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Approach:biophysical modeling· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Bosshart· 2 shared A. Cornelius· 2 shared A. Neculcea· 2 shared C. Iss· 2 shared C. Wang· 2 shared C. Zitt· 2 shared D. L. Hurdiss· 2 shared D. Schaible· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Bosshart

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Nanothermometry-enabled intelligent laser tissue soldering

O. Cipolato, L. Dosnon, J. Rosendorf, S. Sarcevic, A. Bondi, V. Liska, A. Schlegel, I. K. Herrmann

This paper introduces iSoldering, a laser tissue soldering technique with integrated nanothermometry to enable precise temperature control and high-performance tissue sealing.

bioRxiv · Mar 3, 2023Bioengineering

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants

S. Rothenberger, D. L. Hurdiss, M. Walser, F. Malvezzi, J. Mayor, S. Ryter, H. Moreno, N. Liechti, A. Bosshart, C. Iss, V. Calabro, A. Cornelius, T. Hospodarsch, A. Neculcea, T. Looser, , Vassell

This paper describes ensovibep, a trispecific DARPin that inhibits SARS-CoV-2 variants by targeting the spike protein, showing potent antiviral activity and protection in animal models.

bioRxiv · Feb 3, 2021 · PreprintImmunology

Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates

M. Walser, S. Rothenberger, D. L. Hurdiss, A. Schlegel, V. Calabro, S. Fontaine, D. Villemagne, M. Paladino, T. Hospodarsch, A. Neculcea, A. Cornelius, P. Schildknecht, M. Matzner, M. Haenggi, M. Franchini, , Stittela

This paper develops potent anti-SARS-CoV-2 DARPin therapeutics with low picomolar neutralization efficacy and reports their protective efficacy in a hamster model.

bioRxiv · Aug 25, 2020 · PreprintImmunology